Key Market Insights
 Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles
 At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach
 Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers
 Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route
 Industry stakeholders are steadily expanding their existing capabilities in order to enhance their respective service portfolios and drive compliance to evolving industry benchmarks
 A rise in partnerships focused on bioavailability enhancement services and technology platforms validate the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions
 In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions
 5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby, indicating the rapid pace of research activity within this domain
 Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio; we identified over 9,900 such patents
 With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition
 Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future
 Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035
 The estimated market opportunity is expected to be well distributed across different types of drug classes, dosage forms and key geographical regions.





Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3.1. Chapter Overview
3.2. Historical Overview of Bioavailability
3.3. Assessment of Drug Bioavailability
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
3.6. Bioavailability Enhancement Technologies
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle
4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1.Analysis by Solid Dispersion Approaches
4.2.5.2.Analysis by Size Reduction Approaches
4.2.5.3.Analysis by Lipid-Based Approaches
4.2.5.4.Analysis by Other Bioavailability Enhancement Approaches
4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach

5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.3. Ascendia Pharmaceuticals
7.4. Catalent
7.5. Formulex Pharma Innovations (formerly SoluBest)
7.6. Lonza
7.7. Lubrizol Life Science Health
7.8. Pace Analytical
7.9. Quotient Sciences
7.10. WuXi STA (A Subsidiary of WuXi AppTec)

8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Bioavailability Enhancement Approach
10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach
10.3.5. Most Popular Journals: Analysis by Number of Publications
10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
10.3.7. Most Popular Publishers: Analysis by Number of Publications
10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
11.3.1. Analysis by Application Year
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Bioavailability Enhancement Approach
11.3.4. Analysis by CPC Symbols
11.3.5. Analysis by Geography
11.3.6. Analysis by Emerging Focus Areas
11.3.7. Analysis by Type of Organization
11.3.8. Leading Players: Analysis by Number of Patents
11.4. Drug Bioavailability Enhancement Market: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
12.3.1. Research Methodology
12.3.2. Analysis of Trials by Trial Registration Year
12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.4. Analysis of Trials by Study Design
12.3.5. Analysis of Trials by Trial Phase
12.3.6. Analysis of Trials by Trial Recruitment Status
12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
12.3.8. Analysis by Type of Molecule and Trial Phase
12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Study Focus
12.3.12. Analysis of Trials by Geography
12.3.13. Analysis of Enrolled Patient Population by Geography

13. TECHNOLOGY EVALUATION FRAMEWORK
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Technologies based on Solid Dispersion Approaches
13.3.1 List of Approved Drugs
13.3.2 Trends in Intellectual Capital
13.3.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.4. Technologies based on Size Reduction Approaches
13.4.1 List of Approved Drugs
13.4.2 Trends in Intellectual Property
13.4.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.5. Technologies based on Lipid-based Approaches
13.5.1 List of Approved Drugs
13.5.2 Trends in Intellectual Property
13.5.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.6. Technology Evaluation Framework: Wind Rose Representation
13.7. Technology Evaluation Framework: Spider Web Representation
13.8. Results and Discussions

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
14.4. Analysis by Drug Class, 2022 and 2035
14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
14.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035
14.5. Analysis by BCS Classification, 2022 and 2035
14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035
14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035
14.6. Analysis by Dosage Form, 2022 and 2035
14.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035
14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035
14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035
14.6.4. Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035
14.7. Concluding Remarks

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Bioavailability Enhancement Services Market, 2022-2035
15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035
15.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035
15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035
15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches, 2022-2035
15.6.2. Bioavailability Enhancement Services Market for Size Reduction Approaches, 2022-2035
15.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Approaches, 2022-2035
15.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, 2022-2035
15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
15.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
15.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035
15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035
15.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
15.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
15.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
15.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
15.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035
15.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
15.9. Concluding Remarks

16. CONCLUSION

17. APPENDIX I: LIST OF COMPANIES

18. APPENDIX II: TABULATED DATA


Get more details on the Bioavailability Enhancement Technologies and Services Market report https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html

Learn from experts: do you know about these emerging industry trends?
Single-use Bioreactor: An Indispensable Component for Biopharmaceutical Manufacturing
Bacteriophage Therapy – A Revolutionary Approach Towards Multi-Resistant Bacteria
Top 5 Companies Developing Tangential Flow Filtration Systems Used in Biologics Industry

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]